Thursday, February 7, 2013- 4 Healthcare Stock Stories for The Day Before Fridayat Wall St. Cheat Sheet (Thu, Feb 7)
- The Investor's Guide to Zoetisat Motley Fool (Thu, Feb 7)
- Lilly Halts Testing of Rheumatoid Arthritis Medicineat Bloomberg (Thu, Feb 7)
- If You're Going to Fail, Fail Quicklyat Motley Fool (Thu, Feb 7)
- Amgen's Planned Assault On AbbVie, Roche, And Lillyat Forbes (Thu, Feb 7)
- The Expense Of Diabetes: Is It Worth It?at Motley Fool (Thu, Feb 7)
- Teva Pharmaceutical 4Q profit falls 37 percentAP (Thu, Feb 7)
- Lilly stops rheumatoid arthritis treatment studyAP (Thu, Feb 7)
- Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy ResultsPR Newswire (Thu, Feb 7)
Wednesday, February 6, 2013 Tuesday, February 5, 2013- Biggest civil settlements for Justice Dept.AP (Tue, Feb 5)
- Can Anything Stop Novo Nordisk?at Seeking Alpha (Tue, Feb 5)
- January Top 10: Furiexat Motley Fool (Tue, Feb 5)
- Bayer Presents Positive ATX101 DataZacks (Tue, Feb 5)
- Lots of biotech M&A expected in 2013, but it may be a seller’s marketat bizjournals.com (Tue, Feb 5)
- SHPG Reaches Agreement with US GovtZacks (Tue, Feb 5)
- CAPScall of the Week: Zoetisat Motley Fool (Tue, Feb 5)
- Steven Soderbergh's Outrageous Statement About Erectile Dysfunction Side-Effectsat Forbes (Tue, Feb 5)
- Lilly Recognized for Fifth Straight Year on NAFE's 'Top 50 Companies for Executive Women'PR Newswire (Tue, Feb 5)
- Forest Laboratories Goes Off Lexapro- What Happens Next?at Seeking Alpha (Tue, Feb 5)
- Incyte Pharmaceuticals Is Primed For A Runat Seeking Alpha (Tue, Feb 5)
Add LLY News to My Yahoo!   | |
|
0.60(1.10%) May 24, 4:00PM EDT|After Hours
:
54.14 0.00 (0.00%) May 24, 5:42PM EDT